Table 1.
Baseline demographics and characteristics of the study participants
| Placebo (n = 80) | Evogliptin (n = 80) | |
|---|---|---|
| Age, years | 56.8 ± 9.8 | 57.6 ± 11.0 |
| Men, n (%) | 46 (57.5) | 39 (48.8) |
| Weight, kg | 67.2 ± 10.8 | 67.6 ± 11.5 |
| BMI, kg/m2 | 25.4 ± 3.4 | 25.6 ± 3.2 |
| eGFRa, mL/min/1.73 m2 | 88.6 ± 18.6 | 88.6 ± 21.5 |
| Diabetes durationb, years | 4.25 ± 4.10 | 4.74 ± 3.81 |
| ≤4 weeks, n (%) | 28 (35) | 20 (25) |
| >4 weeks, n (%) | 52 (65) | 60 (75) |
| HbA1c, % | 7.20 ± 0.63 | 7.21 ± 0.56 |
| HbA1c < 8.5%, n (%) | 75 (93.8) | 78 (97.5) |
| HbA1c ≥ 8.5%, n (%) | 5 (6.3) | 2 (2.5) |
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin. Values are expressed as mean ± s.d.
a
eGFR estimated from serum creatinine using Modification of Diet in Renal Disease Study equation.
b
Duration of diabetes was calculated as the number of years between the day of consent and the day of diagnosis of T2D.